Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$107.49 USD
-0.09 (-0.08%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $107.25 -0.24 (-0.22%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABT 107.49 -0.09(-0.08%)
Will ABT be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ABT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABT
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True?
Abbott (ABT) Stock Dips While Market Gains: Key Facts
ABT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
DexCom (DXCM) Declines on Potential Competition for Stelo (revised)
DexCom (DXCM) Declines on Potential Competition for Stelo
Other News for ABT
Wells Fargo Remains a Buy on Abbott Laboratories (ABT)
4 constructive medical devices stocks - BTIG
Abbott Laboratories's Options: A Look at What the Big Money is Thinking
Abbott Laboratories (ABT)'s Winning Formula: Financial Metrics and Competitive Strengths
Abbott Receives U.S. FDA Clearance for Two New Over-the-Counter Continuous Glucose Monitoring Systems